ClinicalTrials.gg
CompletedNCT00570128Updated Apr 19, 2021Results posted

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

A Phase 2 interventional study of Donepezil HCl and Placebo in Down Syndrome, sponsored by Eisai Inc.. Completed at 31 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 205 studies in Down Syndrome with a site in United States — 48 open to participants now, 56 under way, 4 of them phase 3. Down Syndrome · United States.

Enrollment
23rd of 131
129 · median 40
Started
2007
with 1 other
Phase 2
23 of 205
8 open now
Registered
6th of 205
by date

Among the 205 studies in Down Syndrome with a site in United States, this one is the 23rd largest by enrollment of the 131 interventional ones that give a count, is one of 2 that started in 2007, is one of 23 in phase 2, and was the 6th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

48 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Down Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether donepezil HCl is effective and safe in improving cognitive dysfunction exhibited by children and adolescents with Down syndrome (DS). Effectiveness will be measured by rating communication, daily living skills, and social skills and relationships in subjects aged 10 to 17.

03

Conditions studied

  • Down Syndrome

Browse trials for

Keywords

  • Down Syndrome
  • trisomy 21
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 10 to 17 years old, weight more than or equal to 20 kg
  • Male and female
  • Vineland-II Adaptive Behavior Scales (VABS-II)/Parent/Caregiver Rating Form (PCRF) standard composite score greater than (>) 55
  • Diagnosis of DS (trisomy 21) documented by chromosomal analysis (karyotyping). If such documentation is not available at screening, karyotyping will be performed with the screening labs and must be documented prior to baseline visit.
  • Naïve to approved or unapproved cholinesterase inhibitors is preferred however, prior use of these medications is allowed, provided that the medication was discontinued at least 3 months prior to screening and that it was not discontinued for lack of tolerability or efficacy or for the sole purpose of enrolling the subject in the study.
  • Subjects residing in the community
  • Must be expected to complete all procedures scheduled during the Screening and Baseline visits including all efficacy and safety parameters.
  • Must speak English and be verbal and able to be understood most of the time and must not use other forms of communication, signs, symbol boards or devices to supplement his/her communication ability
  • Must have a parent or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
  • a Parent or Caregiver must be a constant and reliable informant with sufficient contact with the subject to have detailed knowledge of the subject's adaptive behavior in order to be able to complete the VABS-II/PCRF accurately. The same individual should complete the form at every visit.
  • Should be in good general health with no medical conditions that are considered both and unstable
  • Clinical laboratory values within normal limits or abnormalities considered not clinically significant by the investigator and sponsor
  • Stable Type I (insulin-dependent) or Type II diabetes are eligible provided they are monitored regularly prior to and during the study to ensure adequate glucose control (fasting blood glucose \<140 milligram per deciliter (mg/dl) and glycosylated [] \<8 percent (%) at screening).
  • Thyroid disease also may be included in the study provided they are euthyroid and stable on treatment for at least 3 months prior to screening.
  • History of seizure disorder is allowed provided that subjects are on stable treatment for at least 3 months and have not had a seizure within the past 6 months.
  • Independent in ambulation or ambulatory aided (example, walker or cane, wheelchair), vision and hearing (eyeglasses and/or hearing aid permissible) sufficient for achieving VABS-II/PCRF composite standard scores >55 and for cooperating with examinations and the Test of Verbal Expression and Reasoning (TOVER).

Exclusion criteria

Exclusion Criteria:

  • Ages \<10 or >17 years
  • Active or conditions affecting absorption, distribution or metabolism of the study medication (example, inflammatory bowel disease, gastric or duodenal ulcers or severe lactose intolerance)
  • Known to piperidine derivatives or cholinesterase inhibitors
  • Currently receiving cholinesterase inhibitors or who have received them in the 3 months prior to screening or with prior use >3 months prior to screening who stopped for lack of efficacy or tolerability
  • No reliable parent or caregiver, or participants, or caregivers who are unwilling or unable to complete any of the outcome measures and fulfill the requirements of this study
  • Clinically significant obstructive pulmonary disease or asthma untreated or not controlled by treatment within 3 months prior to screening
  • Recent (less than or equal to 2 years) hematologic/oncologic disorders (mild anemia allowed)
  • Evidence of active, clinically significant, and unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease
  • Current Diagnostic and Statistical Manual IV Text Revision () diagnosis of Major Depressive Disorder (MDD) or any current primary psychiatric diagnosis other than DS (as per DSM-IV)
  • Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study
  • Unsuitability which includes female subjects who have begun menstruation and are thus of , who may be sexually active and who are not practicing an effective means of .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Active comparator
    Donepezil HCl

    Drug: Donepezil HCl

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).

    Also known as: Aricept

  • DrugPlacebo

    Liquid formulation matched to active treatment for oral administration.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 10-Last Observation Carried Forward (LOCF)

    The VABS-II/PCRF instrument was used in this study to assess 3 domains (each with 3 sub-domains): communication (sub-domains: receptive, expressive, and writing), daily living skills (sub-domains: personal, domestic, community), and socialization (sub-domains: interpersonal relationships, play/leisure time, coping skills). Raw scores (2=always present, 1=sometimes present, 0=seldom or never present) rated by the parent/caregiver from each sub-domain were converted to standardized scores called V-scores, which are based on age and a national sample of normal children. Each sub-domain v-scale score ranged from 1 (weakness) to 24 (strength). V-scores for the 9 sub-domains were summed to obtain a composite V-score ranging from 9 to 216. Higher scores indicate a higher level of adaptive functioning. A positive change from baseline indicates an improvement in adaptive functioning. Composite V-scores have a mean (50th percentile) of 100 and a standard deviation (SD) of 15.

    Time frame: Baseline, Week 10

Secondary outcomes

  1. Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 4 and 10-Observed Cases (OC)

    The VABS-II/PCRF instrument was used in this study to assess 3 domains (each with 3 sub-domains): communication (sub-domains: receptive, expressive, writing), daily living skills (sub-domains: personal, domestic, community), and socialization (sub-domains: interpersonal relationships, play/leisure time, coping skills). Raw scores (2=always present, 1=sometimes present, 0=seldom or never present) rated by the parent/caregiver from each sub-domain were converted to standardized scores called V-scores, which are based on age and a national sample of normal children. Each sub-domain v-scale score ranged from 1 (weakness) to 24 (strength). V-scores for the 9 sub-domains were summed to obtain a composite V-score ranging from 9 to 216. Higher scores indicate a higher level of adaptive functioning. A positive change from baseline indicates an improvement in adaptive functioning. Composite V-scores have a mean (50th percentile) of 100 and a SD of 15.

    Time frame: Baseline, Week 4 and Week 10

  2. Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 4 and 10-OC

    The TOVER is a participant-performance-based measure of expressive language function and verbal reasoning in response to questions about a series of stylized pictures showing identifiable scenarios. The 64-item test was specifically designed to assess language function in children and adults with down syndrome (DS) across a broad range of functional ability. The test used 23 multi-colored pictures to stimulate verbal responses to questions. The test was short (completed in 15 minutes) and fast-paced (2 to 4 questions per picture). Total score ranging from 0 to 64, was derived from 64 questions, where higher score indicates better functional ability.

    Time frame: Baseline, Week 4 and Week 10

  3. Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 10-LOCF

    The TOVER is a participant-performance-based measure of expressive language function and verbal reasoning in response to questions about a series of stylized pictures showing identifiable scenarios. The 64-item test was specifically designed to assess language function in children and adults with DS across a broad range of functional ability. The test used 23 multi-colored pictures to stimulate verbal responses to questions. The test was short (completed in 15 minutes) and fast-paced (2 to 4 questions per picture). Total score ranging from 0 to 64, was derived from 64 questions, where higher score indicates better functional ability.

    Time frame: Baseline, Week 10

07

Results

Posted Apr 19, 2021

Participant flow

This study was conducted at 35 centers in the United States during the period of 16 November 2007 to 05 September 2008.

Participant flow — Overall Study
MilestoneDonepezil HClPlacebo
Started6465
Intent to treat (itt) population6265
Completed6065
Not completed40
Withdrew: Adverse event10
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryMean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 10-Last Observation Carried Forward (LOCF)

The VABS-II/PCRF instrument was used in this study to assess 3 domains (each with 3 sub-domains): communication (sub-domains: receptive, expressive, and writing), daily living skills (sub-domains: personal, domestic, community), and socialization (sub-domains: interpersonal relationships, play/leisure time, coping skills). Raw scores (2=always present, 1=sometimes present, 0=seldom or never present) rated by the parent/caregiver from each sub-domain were converted to standardized scores called V-scores, which are based on age and a national sample of normal children. Each sub-domain v-scale score ranged from 1 (weakness) to 24 (strength). V-scores for the 9 sub-domains were summed to obtain a composite V-score ranging from 9 to 216. Higher scores indicate a higher level of adaptive functioning. A positive change from baseline indicates an improvement in adaptive functioning. Composite V-scores have a mean (50th percentile) of 100 and a standard deviation (SD) of 15.

Time frame:
Baseline, Week 10
Reported as:
Mean · score on a scale
Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 10-Last Observation Carried Forward (LOCF)
score on a scaleDonepezil HClPlacebo
Baseline83.1 ± 15.585.7 ± 15.8
Mean change from baseline at Week 104.74 ± 9.24.22 ± 8.5
SecondaryMean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 4 and 10-Observed Cases (OC)

The VABS-II/PCRF instrument was used in this study to assess 3 domains (each with 3 sub-domains): communication (sub-domains: receptive, expressive, writing), daily living skills (sub-domains: personal, domestic, community), and socialization (sub-domains: interpersonal relationships, play/leisure time, coping skills). Raw scores (2=always present, 1=sometimes present, 0=seldom or never present) rated by the parent/caregiver from each sub-domain were converted to standardized scores called V-scores, which are based on age and a national sample of normal children. Each sub-domain v-scale score ranged from 1 (weakness) to 24 (strength). V-scores for the 9 sub-domains were summed to obtain a composite V-score ranging from 9 to 216. Higher scores indicate a higher level of adaptive functioning. A positive change from baseline indicates an improvement in adaptive functioning. Composite V-scores have a mean (50th percentile) of 100 and a SD of 15.

Time frame:
Baseline, Week 4 and Week 10
Reported as:
Mean · score on a scale
Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form (VABS-II/PCRF) at Week 4 and 10-Observed Cases (OC)
score on a scaleDonepezil HClPlacebo
Baseline83.1 ± 15.585.7 ± 15.8
Mean change from baseline at Week 41.5 ± 6.42.6 ± 8.5
Mean change from baseline at Week 105.1 ± 9.64.2 ± 8.6
SecondaryMean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 4 and 10-OC

The TOVER is a participant-performance-based measure of expressive language function and verbal reasoning in response to questions about a series of stylized pictures showing identifiable scenarios. The 64-item test was specifically designed to assess language function in children and adults with down syndrome (DS) across a broad range of functional ability. The test used 23 multi-colored pictures to stimulate verbal responses to questions. The test was short (completed in 15 minutes) and fast-paced (2 to 4 questions per picture). Total score ranging from 0 to 64, was derived from 64 questions, where higher score indicates better functional ability.

Time frame:
Baseline, Week 4 and Week 10
Reported as:
Mean · score on a scale
Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 4 and 10-OC
score on a scaleDonepezil HClPlacebo
Baseline20.7 ± 12.221.6 ± 11.4
Mean change from baseline at Week 41.2 ± 6.40.9 ± 8.5
Mean change from baseline at Week 102.6 ± 6.21.9 ± 5.5
SecondaryMean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 10-LOCF

The TOVER is a participant-performance-based measure of expressive language function and verbal reasoning in response to questions about a series of stylized pictures showing identifiable scenarios. The 64-item test was specifically designed to assess language function in children and adults with DS across a broad range of functional ability. The test used 23 multi-colored pictures to stimulate verbal responses to questions. The test was short (completed in 15 minutes) and fast-paced (2 to 4 questions per picture). Total score ranging from 0 to 64, was derived from 64 questions, where higher score indicates better functional ability.

Time frame:
Baseline, Week 10
Reported as:
Mean · score on a scale
Mean Change From Baseline in Test of Verbal Expression and Reasoning (TOVER) Total Score at Week 10-LOCF
score on a scaleDonepezil HClPlacebo
Baseline20.7 ± 12.221.6 ± 11.4
Mean change from baseline at Week 102.4 ± 6.02.1 ± 5.5

Adverse events

Collected over Baseline up to 10 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil HCl0/64 (0%)0/64 (0%)45/64 (70.3%)
Placebo0/65 (0%)1/65 (1.5%)42/65 (64.6%)
Most frequent serious events
Most frequent serious events
EventDonepezil HClPlacebo
GastroenteritisInfections and infestations0/641/65
DehydrationMetabolism and nutrition disorders0/641/65
Most frequent other events
Showing 10 of 26
Most frequent other events
EventDonepezil HClPlacebo
DiarrheaGastrointestinal disorders11/6410/65
VomitingGastrointestinal disorders8/642/65
Upper respiratory tract infectionInfections and infestations6/645/65
NauseaGastrointestinal disorders5/642/65
HeadacheNervous system disorders5/642/65
CoughRespiratory, thoracic and mediastinal disorders4/641/65
NasopharyngitisInfections and infestations0/644/65
PharyngitisInfections and infestations3/641/65
RashSkin and subcutaneous tissue disorders3/642/65
Ear infectionInfections and infestations1/643/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)Donepezil HClPlaceboTotal
Mean13.0 ± 2.313.0 ± 2.113.0 ± 2.3
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil HClPlaceboTotal
Female283563
Male363066
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Donepezil HClPlaceboTotal
American Indian or Alaska Native000
Asian145
Native Hawaiian or Other Pacific Islander000
Black or African American336
White5457111
More than one race000
Unknown or Not Reported617
08

Study locations

31 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Clinical Study Centers, L.L.C.
    Little Rock, Arkansas 72205, United States
  • Neufeld Medical Group, Inc.
    Los Angeles, California 90048, United States
  • Children's Hospital and Research Center at Oakland
    Oakland, California 94609, United States
  • University of California, Irvine Medical Center, Department of Pediatrics
    Orange, California 92868, United States
  • UCSD Pediatric Pharmacology Research Unit
    San Diego, California 92123, United States
  • Rocky Mountain Pediatrics
    Lakewood, Colorado 80214, United States
  • Neuropsychiatric Research Center of South West Florida
    Fort Myers, Florida 33912, United States
  • Miami Children's Hospital, Clinical Research Center
    Miami, Florida 33155-3009, United States
  • Community Research Foundation
    Miami, Florida 33155, United States
  • Miami Children's Hospital, Brain Institute
    Miami, Florida 33155, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Lazlo J. Mate, MD
    West Palm Beach, Florida 33407, United States
  • Child Neurology Associates, PC
    Atlanta, Georgia 30342, United States
  • Medical Genetics and Neuro Development Center
    Zionsville, Indiana 46077, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • Saint Mayr's Health Care
    Grand Rapids, Michigan 49503, United States
  • Regions Hospital
    Saint Paul, Minnesota 55101-2529, United States
  • Washington University School of Medicine, Division of Genetics and Genomic Medicine
    Saint Louis, Missouri 63110, United States
  • Midwest Children's Health Research Institute, LLC
    Lincoln, Nebraska 68504, United States
  • Clinical Research Center of New Jersey
    Voorhees, New Jersey 08043, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Metrohealth Medical Center, Division of Psychiatry
    Cleveland, Ohio 44109, United States
  • Valko and Associates
    Toledo, Ohio 43606, United States
  • Tulsa Clinical Research LLC
    Tulsa, Oklahoma 74104-5428, United States
  • Medical University of South Carolina, Division of Genetics and Developmental and Behavioral Pediatrics
    Charleston, South Carolina 29425, United States
  • Vanderbilt Children's Hospital
    Nashville, Tennessee 37232-9225, United States
  • Down Syndrome Clinic of Houston
    Houston, Texas 77030, United States
  • Alamo City Clinical Research, LLC
    San Antonio, Texas 78258, United States
  • Road Runner Research
    San Antonio, Texas 78258, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in Sep 2008, 9 months.

Results were first posted in Apr 2021, 12 years 7 months after primary completion.

Of 21 phase 2 interventional studies under Down Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 61. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2007
First posted
Dec 10, 2007
StartActual
Nov 16, 2007
Primary completionActual
Sep 5, 2008
CompletionActual
Sep 5, 2008
Results first posted
Apr 19, 2021
Last update
Apr 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00570128
Lead sponsor
Eisai Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 10, 2007
Start date
Nov 16, 2007
Primary completion
Sep 5, 2008
Completion
Sep 5, 2008
Results posted
Apr 19, 2021
Last update
Apr 19, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion